Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel
about
Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trialRepository corticotropin injection in a patient presenting with focal segmental glomerulosclerosis, rheumatoid arthritis, and optic neuritis: a case report.Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study.Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series.Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series.Pharmacological treatment of primary membranous nephropathy in 2016.The renaissance of corticotropin therapy in proteinuric nephropathiesTreatment of acute relapses in multiple sclerosis.Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis.MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy.Treatment of idiopathic FSGS with adrenocorticotropic hormone gel.Leveraging melanocortin pathways to treat glomerular diseases.Adrenocorticotropic hormone therapy for the treatment of idiopathic nephrotic syndrome in children and young adults: a systematic review of early clinical studies with contemporary relevance.Membranous nephropathy: the start of a paradigm shift.Pathogenesis of membranous nephropathy: recent advances and future challenges.New diagnostic tests and new therapies for glomerular diseases.A review of the re-emergence of adrenocorticotrophic hormone therapy in glomerular disease, more than a drug of last resort?Acquired Resistance to Corticotropin Therapy in Nephrotic Syndrome: Role of De Novo Neutralizing Antibody.Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key IndicationsThe Role of Alpha-MSH as a Modulator of Ocular Immunobiology Exemplifies Mechanistic Differences between Melanocortins and Steroids.Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis.Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases: a systematic review and meta-analysis.Low-dose synthetic adrenocorticotropic hormone-analog therapy for nephrotic patients: results from a single-center pilot study.Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor.Membranous glomerulopathy and treatment with Acthar®: a case study.Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation.Use of synthetic adrenocorticotropic hormone in patients with IgA nephropathy.Amplification of the Melanocortin-1 Receptor in Nephrotic Syndrome Identifies a Target for Podocyte Cytoskeleton Stabilization
P2860
Q34512800-A92476E4-7028-4A36-8E8D-0B1B9CE4F439Q35219562-9403B011-34EB-4712-BCCD-7EF7220EE479Q35840057-33B1D9E0-BA35-47E1-B69E-15769E0B0B69Q35976834-5683A28D-2BBD-4E86-ADA0-D5465A48D780Q36083205-382C3C78-99C9-48D9-8441-91CA271E04BCQ36106413-5E7673C2-156E-4804-8711-A9A37487C31EQ36520242-D86CB197-251E-45DE-96CF-98BA788E7804Q36568671-5A552DE7-D2DA-411E-93F0-D7350F6BECC2Q36613389-ABB3F5EB-60CF-401C-A922-3663C18E3628Q36980645-DC21509F-08A3-4A69-8095-3824FF78FC37Q37359035-92B806B3-8DE7-447B-B881-D65F6DD34171Q37632054-E7E8CFAA-492D-4A94-97A3-EFB2B130E227Q37651364-7F482B9B-9320-4F57-A4D1-B574439D3951Q37975360-61279343-EB0E-4AEC-B3D8-419F0CD9DA98Q37988806-79827D71-B7A2-4799-80A6-19F6D8494A28Q38076221-6A6F3A7B-B9A3-4308-881E-6A7359F41804Q38562318-37265445-A578-41A6-99D7-AC74172D0E48Q38667777-5CBD574F-3B7B-4FDB-9905-4001F3D1DD91Q38703169-5A17A66E-7FD3-4D94-972D-F8CF6DFA94B7Q38710638-FD5C8399-74E8-4EFE-9D54-C0B2E1409924Q38738516-BFA890EA-DBAD-40D7-AB5B-C7DE30A5AB1BQ38858772-F39B5692-A65A-4B50-8A24-A42292EDE36BQ41467613-8004CA64-2F27-49CB-A9BC-B18456AA29FFQ41688065-F527495C-FD72-478D-BBD3-BAA6E6DE38F1Q41774545-B70AFA31-BD0C-482C-AA33-FBE2A83D1734Q42654718-5583B676-F745-42E7-A4D6-326FA3FAA71EQ46594445-16776A22-38E7-46FA-AFE8-FC7FD3878186Q55424564-ADA51889-8123-4D3B-8502-13C2415ADED0Q57794745-B6D7C0AA-8E1C-4E3F-9B09-FA706FCD4C70
P2860
Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel
@ast
Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel
@en
Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel
@nl
type
label
Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel
@ast
Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel
@en
Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel
@nl
prefLabel
Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel
@ast
Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel
@en
Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel
@nl
P2093
P2860
P3181
P356
P1476
Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel
@en
P2093
Alice S Appel
Anatole Besarab
Andrew S Bomback
Gerald B Appel
Jai Radhakrishnan
James A Tumlin
James E Bourdeau
Joel Baranski
P2860
P304
P3181
P356
10.2147/DDDT.S17521
P407
P577
2011-01-01T00:00:00Z